Evidence map›Paper›PMID 35321506›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Mechanism of Herb Pairs

Zixuan Wu, Xiyang Pan, Chaosheng Deng, Minjie Cai, Kai Yuan, Peidong Huang, Guoqi Shi

Abstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zixuan WuGuangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.ORCID https://orcid.org/0000-0002-2993-9949
Xiyang PanGuangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.ORCID https://orcid.org/0000-0002-5438-7306
Chaosheng DengGuangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.ORCID https://orcid.org/0000-0002-4484-6871
Minjie CaiShantou Health School, Shantou, Guangdong 515061, China.ORCID https://orcid.org/0000-0001-6379-5208
Kai YuanYunnan University of Chinese Medicine, Kunming, Yunnan 650500, China.ORCID https://orcid.org/0000-0003-2790-8206
Peidong HuangYunnan University of Chinese Medicine, Kunming, Yunnan 650500, China.ORCID https://orcid.org/0000-0001-6558-9088
Guoqi ShiGuangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China.ORCID https://orcid.org/0000-0003-1126-758X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric carcinoma (GC) is a kind of digestive tract tumor that is highly malignant and has a very poor prognosis. Although both Materials and Methods: The traditional Chinese medicine network databases TCMSP, TCMID, and ETCM were used to identify the key functional components and associated targets of AM and CPV. To establish a theoretical foundation, the development of gastric cancer (GC) was predicted utilizing a GEO gene chip and TCGA difference analysis mixed with network pharmacology. A herbal-ingredient-target network and a core target-signal pathway network were created using GO and KEGG enrichment analyses. The molecular docking method was used to evaluate seventeen main targets and their compounds. Results: Cell activity, reactive oxygen species modification, metabolic regulation, and systemic immune activation may all be involved in the action mechanism of the AM-CPV drug-pair in the treatment of GC. It inhibits the calcium signaling route, the AGE-RAGE signaling system, the cAMP signaling pathway, the PI3K-Akt signaling network, and the MAPK signaling pathway, slowing the progression of GC. The number of inflammatory substances in the tumor microenvironment is reduced, GC cell proliferation is deprived, apoptosis is promoted, and GC progression is retarded through controlling the IL-17 signaling route, TNF signaling pathway, and other inflammation-related pathways. Conclusions: The AM-CPV pharmaceutical combination regulates GC treatment via a multitarget, component, and signal pathway with a cooperative and bidirectional regulatory mechanism. Its active constituents may treat GC by regulating the expression of STAT1, MMP9, IL6, HSP90AA1, JUN, CCL2, IFNG, CXCL8, and other targets, as well as activating or inhibiting immune-inflammatory and cancer signaling pathways.

Identifiers

PMID35321506
PMCPMC8938068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.